Emergent Biosolutions (NYSE:EBS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Emergent Biosolutions (NYSE:EBS) from a buy rating to a strong-buy rating in a research note issued to investors on Sunday morning.

A number of other research analysts have also weighed in on EBS. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Emergent Biosolutions in a report on Wednesday, September 3rd. Zacks Research raised Emergent Biosolutions to a “hold” rating in a report on Friday, October 24th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Emergent Biosolutions in a research note on Tuesday, November 25th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $15.00.

Emergent Biosolutions Trading Up 0.6%

Shares of Emergent Biosolutions stock opened at $10.86 on Friday. The firm has a market cap of $570.26 million, a price-to-earnings ratio of 8.35 and a beta of 2.32. Emergent Biosolutions has a 52-week low of $4.02 and a 52-week high of $13.41. The company’s 50-day simple moving average is $9.96 and its 200-day simple moving average is $8.22. The company has a quick ratio of 3.15, a current ratio of 5.76 and a debt-to-equity ratio of 1.14.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) EPS for the quarter. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 20.85%. The firm had revenue of $222.50 million during the quarter. As a group, equities research analysts anticipate that Emergent Biosolutions will post -0.63 earnings per share for the current year.

Insider Activity at Emergent Biosolutions

In related news, EVP Coleen Glessner sold 30,608 shares of the stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $10.00, for a total value of $306,080.00. Following the sale, the executive vice president directly owned 144,319 shares of the company’s stock, valued at approximately $1,443,190. This represents a 17.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC raised its holdings in shares of Emergent Biosolutions by 313.5% in the first quarter. Acadian Asset Management LLC now owns 833,316 shares of the biopharmaceutical company’s stock worth $4,048,000 after acquiring an additional 631,794 shares during the last quarter. Wolverine Asset Management LLC boosted its stake in shares of Emergent Biosolutions by 28.3% during the second quarter. Wolverine Asset Management LLC now owns 174,933 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 38,600 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Emergent Biosolutions by 12.5% during the first quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock valued at $5,301,000 after acquiring an additional 121,583 shares during the last quarter. Hussman Strategic Advisors Inc. increased its position in Emergent Biosolutions by 400.0% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 105,000 shares of the biopharmaceutical company’s stock worth $670,000 after purchasing an additional 84,000 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new position in Emergent Biosolutions in the 2nd quarter valued at about $227,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.